Pharma Pulse 2/3/25: Why Frontline Sales Will Continue to Lead to Long-term Career Success, Gene Therapy’s Pipeline Has a Steady Flow & more
The latest news for pharma industry insiders.
Why Frontline Sales Have and Will Continue to be a Foundation for Long-term Career Success
Paul Ollinger is a writer, stand-up comedian, and host of the Reasonably Happy podcast (fka, Crazy Money). Prior to his pivot to the entertainment industry, Ollinger worked in a variety of sales roles including LAUNCH.com, Yahoo and Facebook (now Meta) where he was vice president of West Coast Sales and one of the first 250 employees. Ollinger earned his MBA from Dartmouth's Tuck School.
Gene Therapy’s Pipeline Has a Steady Flow of More Than 2,000 Candidates
The majority are in the very early preclinical stage of development, but applications for regulatory approval have been submitted for 11 gene therapies worldwide, and 35 are in phase 3 trials, according to report delineating the gene therapy development landscape.
New Pain Drug Gets FDA Nod as Safer Alternative to Addictive Opioids
Vertex Pharmaceuticals Inc. gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been linked to hundreds of thousands of deaths.
GE HealthCare has announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of the existing site will enable 25 million more patient doses per year of contrast media by the end of 2027, helping address growing global demand.
It's a compelling idea and one that's worth evaluating. The correlation between online search behavior and dispensed prescriptions, as highlighted in the article, suggests that search trends could provide valuable insights into future GLP-1 use. This data might help predict demand, optimize supply chains, and improve education efforts for both providers and patients.
That said, search behavior has its limitations. It can be influenced by factors like marketing campaigns or media coverage, which don't always align with actual clinical adoption or need.
Still, the potential for integrating this type of data into forecasting and planning is intriguing, especially as GLP-1 therapies continue to reshape obesity management.
Thanks for bringing this up, it's definitely a topic worth reflecting on!
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
